𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Intermittent Oral Disodium Pamidronate in Established Osteoporosis: A 2 Year Double-Masked Placebo-Controlled Study of Efficacy and Safety

✍ Scribed by P. J. Ryan; G. M. Blake; M. Davie; M. Haddaway; T. Gibson; I. Fogelman

Publisher
Springer-Verlag
Year
2000
Tongue
English
Weight
77 KB
Volume
11
Category
Article
ISSN
0937-941X

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

MLN3897 plus methotrexate in patients wi
MLN3897 plus methotrexate in patients with rheumatoid arthritis: Safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study
✍ Clarissa E. Vergunst; Danielle M. Gerlag; Lisa von Moltke; Michael Karol; Tim Wy πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 169 KB πŸ‘ 3 views

## Abstract ## Objective To assess the efficacy, safety, pharmacokinetics, and pharmacodynamics of the CC chemokine receptor CCR1 antagonist MLN3897 in patients with rheumatoid arthritis (RA) receiving methotrexate (MTX). ## Methods In this phase IIa, proof‐of‐concept study, patients meeting the

Efficacy and safety of a once-yearly i.v
Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: A randomized, multicenter, double-blind, active-controlled study
✍ Eric S Orwoll; Paul D Miller; Jonathan D Adachi; Jacques Brown; Robert A Adler; πŸ“‚ Article πŸ“… 2010 πŸ› American Society for Bone and Mineral Research 🌐 English βš– 216 KB

## Abstract Zoledronic acid (ZOL) has shown beneficial effects on bone turnover and bone mineral density (BMD) in postmenopausal osteoporosis. This study compared the efficacy and safety of a once‐yearly i.v. infusion of ZOL with weekly oral alendronate (ALN) in men with osteoporosis. In this multi